查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1864567

急性呼吸窘迫症候群(ARDS) 市場按產品類型、治療模式、最終用戶、患者人口統計特徵、嚴重程度、病因和分銷管道分類 - 全球預測 2025-2032 年

Acute Respiratory Distress Syndrome Market by Product Type, Treatment Mode, End User, Patient Population, Severity, Etiology, Distribution Channel - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 189 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，急性呼吸窘迫症候群(ARDS) 市場規模將達 44.4 億美元，複合年成長率為 6.29%。

關鍵市場統計數據
基準年 2024 27.2億美元
預計年份：2025年 29億美元
預測年份 2032 44.4億美元
複合年成長率 (%) 6.29%

為決策者提供一份簡明扼要、全面的急性呼吸窘迫症候群臨床挑戰、技術和操作需求概述。

急性呼吸窘迫症候群(ARDS) 是加護治療醫學、醫療設備創新和醫療保健系統運作領域持續存在的臨床挑戰。本執行摘要整合了最新的證據和行業趨勢，旨在為臨床醫生、採購經理和戰略投資者提供一個清晰的視角，闡述不斷演變的臨床實踐、技術應用促進因素以及影響重度呼吸衰竭患者護理的營運限制。

在三級醫療機構和專科醫療機構中，臨床醫生已調整診療路徑，以整合先進的體外循環療法、複雜的通氣策略和有針對性的支持性干預措施。這些臨床變革與監管機構的嚴格審查和支付方的壓力同步發生，後者強調可驗證的療效和成本控制。因此，技術開發人員和醫療系統領導者正在重新評估其產品開發藍圖和籌資策略，以適應優先考慮互通性、可靠性和對以患者為中心的療效的可衡量影響的環境。

本導言透過強調臨床需求、醫療設備創新和系統促進因素之間的相互作用，為後續分析奠定了框架。它著重指出，需要提供能夠連接技術細節和戰略意義的實用見解，幫助相關人員理解急性呼吸衰竭治療的複雜性及其背後的技術。

深入探討正在重塑急性呼吸照護臨床實務、技術應用和供應鏈策略的變革性轉變

隨著技術、臨床實踐和供應鏈策略的融合，急性呼吸窘迫症候群（ARDS）的治療模式正在經歷一場變革，重塑治療方案和治療路徑。體外支援設備和人工呼吸器設計的進步，使得患者選擇和介入時機的通訊協定更加嚴格，這正在影響醫療系統部署專用設備和組建跨學科團隊的方式。

同時，加護治療環境的數位化和即時監測平台的整合，使得呼吸支援的精準調整和遠端監測得以加強。因此，醫療機構越來越重視支援資料互通性和預測分析的設備。此外，俯臥療法實踐和呼吸耗材的改進也凸顯了醫療機構向能夠提高病人安全和感染控制水平、同時減輕醫護人員負擔的設備和一次性產品轉變的趨勢。

此外，為應對全球衛生危機暴露出的供應鏈脆弱性，籌資策略正在轉變，相關人員尋求供應商多元化並發展區域製造夥伴關係。這些因素共同推動了產品差異化取決於臨床療效、營運效率和韌性的環境發展，為製造商和醫療服務提供者創造了新的合作機遇，共同開發既能滿足當前臨床需求又能永續性的解決方案。

對 2025 年美國關稅對急性呼吸照護領域醫療設備、供應鏈和籌資策略的累積影響進行嚴格檢驗。

美國將於2025年實施的新關稅將對急性呼吸窘迫症候群（ARDS）治療中使用的臨床技術和耗材產生多方面的影響，其累積效應將波及採購、製造和臨床實踐等各個環節。某些醫療設備和組件進口關稅的提高增加了部分先進系統和一次性產品的到岸成本，迫使醫院採購團隊和集團採購組織探索替代籌資策略，以在不降低品質的前提下保持臨床應對力，並重新評估供應商合約。

這些貿易政策的變化加速了關於關鍵部件（尤其是體外膜氧合（ECMO）和先進人工呼吸器中使用的複雜子系統）近岸外包和本地製造的討論。因此，醫療設備開發商和契約製造必須權衡短期成本壓力和對穩定供應的長期投資。對臨床醫生而言，最直接的影響是重新關注設備維護、重新審視適當且安全的重複使用通訊協定以及策略性庫存管理，以降低潛在的供應中斷風險。

此外，供應商越來越重視整體擁有成本 (TCO) 和服務等級協定 (SLA) 的透明度，以贏得機構採購部門的信任。隨著採購團隊要求零件採購路徑透明化，監管合規性和文件記錄也受到越來越嚴格的審查。這些趨勢共同改變了行業的競爭格局，有利於那些能夠展現供應鏈透明度、本地支援以及能夠保護供應商免受貿易相關成本波動影響的靈活商業模式的製造商和經銷商。

透過全面的細分分析，重點關注產品類型、治療路徑、患者群體、疾病通路，為臨床和商業性決策提供支援。

細分市場分析揭示了產品類型、治療模式、醫療環境、患者群體、臨床嚴重程度、原因和通路如何各自影響臨床決策和商業策略。基於產品類型，本研究涵蓋體外膜氧合（ECMO）系統、俯臥通氣系統、呼吸耗材和人工呼吸器。 ECMO系統進一步細分為靜脈-動脈型和靜脈-靜脈型，俯臥通氣系統則分為自動型和手動型。呼吸耗材包括呼吸迴路、過濾器、面罩和介面，人工呼吸器分為有創呼吸器和非人工呼吸器。有創人工呼吸器進一步細分為加護治療人工呼吸器和轉運人工呼吸器，非侵入性人工呼吸器則包括雙水平人工呼吸器和持續性陽壓呼吸器（CPAP）人工呼吸器。

目錄

第1章：序言

第2章調查方法

第3章執行摘要

第4章 市場概覽

第5章 市場洞察

  • 人工呼吸器管理通訊協定利用即時肺部影像和人工智慧決策支援來最佳化ARDS治療效果。
  • 新興的間質幹細胞療法有望減輕 ARDS 患者的肺損傷和發炎。
  • 體外膜氧合（ECMO）系統擴大被加護病房採用，用於治療嚴重的急性呼吸窘迫症候群（ARDS）。
  • 透過將數位肺部監測平台與預測分析結合，最佳化ARDS的氧合策略
  • 增加對吸入式一氧化氮輸送系統（作為ARDS的輔助性治療）的投資和報銷支持
  • 開發精準生物標記，用於嚴重加護治療中ARDS的早期診斷和個體化治療指導

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章急性呼吸窘迫症候群(ARDS) 產品型市場

  • 體外膜氧合系統
    • 靜脈動脈
    • 靜脈-靜脈
  • 俯臥定位系統
    • 自動定位
    • 手動定位
  • 呼吸耗材
    • 氣道迴路
    • 篩選
    • 口罩和介面
  • 人工呼吸器
    • 有創通氣裝置
      • 加護治療人工呼吸器
      • 運輸人工呼吸器
    • 非侵入性通氣設備
      • 雙水平人工呼吸器
      • 持續陽壓呼吸器通氣

第9章急性呼吸窘迫症候群(ARDS) 市場治療方法

  • 體外膜氧合（ECMO）治療
  • 侵入性通氣
  • 非侵入性通氣
  • 伏地

第10章急性呼吸窘迫症候群（ARDS）市場（依最終用戶分類）

  • 門診治療中心
    • 復健中心
    • 專科診所
  • 居家醫療環境
  • 醫院
    • 社區醫院
    • 教學醫院

第11章急性呼吸窘迫症候群（ARDS）市場病患細分

  • 成人版
  • 新生
  • 孩子們

第12章急性呼吸窘迫症候群（ARDS）市場依嚴重程度分類

  • 溫和的
  • 緩和
  • 嚴重

第13章急性呼吸窘迫症候群（ARDS）市場依病因分類

  • 感染疾病
    • 細菌
    • 真菌
    • 病毒性的
  • 非傳染性的
    • 渴望
    • 創傷

第14章急性呼吸窘迫症候群(ARDS) 市集：依通路分類

  • 直銷
  • 電子商務
  • 第三方經銷商

第15章急性呼吸窘迫症候群（ARDS）市場：依地區分類

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第16章急性呼吸窘迫症候群(ARDS) 市場（依組別分類）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第17章 各國急性呼吸窘迫症候群（ARDS）市場

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第18章 競爭格局

  • 2024年市佔率分析
  • FPNV定位矩陣，2024
  • 競爭分析
    • Koninklijke Philips NV
    • Medtronic plc
    • General Electric Company
    • Dragerwerk AG & Co. KGaA
    • Hamilton Medical AG
    • ResMed Inc.
    • Getinge AB
    • Fisher & Paykel Healthcare Corporation Limited
    • Mindray Medical International Limited
    • Nihon Kohden Corporation
Product Code: MRR-4E447E7FCAAC

The Acute Respiratory Distress Syndrome Market is projected to grow by USD 4.44 billion at a CAGR of 6.29% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 2.72 billion
Estimated Year [2025] USD 2.90 billion
Forecast Year [2032] USD 4.44 billion
CAGR (%) 6.29%

A concise yet comprehensive introduction that frames acute respiratory distress syndrome clinical challenges alongside technological and operational imperatives for decision-makers

Acute respiratory distress syndrome presents a persistent clinical challenge that intersects critical care medicine, device innovation, and health systems operations. This executive summary synthesizes contemporary evidence and industry developments, aiming to equip clinicians, procurement leaders, and strategic investors with a coherent view of evolving clinical practices, technology adoption drivers, and operational constraints that shape care delivery for patients experiencing severe respiratory failure.

Across tertiary hospitals and specialized care settings, clinicians have adapted care pathways to integrate advanced extracorporeal therapies, refined ventilation strategies, and targeted supportive interventions. These clinical shifts occur in parallel with regulatory scrutiny and payer pressures that emphasize demonstrable outcomes and cost containment. Consequently, technology developers and health system leaders are recalibrating product development roadmaps and procurement strategies to align with an environment that prizes interoperability, reliability, and measurable impact on patient-centered outcomes.

This introduction frames the subsequent analysis by highlighting the interplay between clinical needs, device innovation, and systemic drivers. It underscores the need for actionable intelligence that bridges technical detail and strategic implications, enabling stakeholders to navigate the complexity of acute respiratory failure care and the technologies that underpin it.

An in-depth exploration of the transformative shifts reshaping clinical practice, technology adoption, and supply chain strategies across acute respiratory care

The landscape for acute respiratory distress syndrome care is undergoing transformative shifts as technology, clinical practice, and supply chain strategies converge to reshape therapeutic options and care pathways. Advances in extracorporeal support and ventilator design are being accompanied by more rigorous protocols for patient selection and timing of interventions, which in turn affect how health systems deploy specialized equipment and train multidisciplinary teams.

Simultaneously, the digitization of critical care environments and the integration of real-time monitoring platforms are enabling more precise titration of respiratory support and enhanced remote oversight. As a result, providers increasingly prioritize equipment that supports data interoperability and predictive analytics. In parallel, the evolution of prone positioning practices and respiratory consumables highlights a move toward devices and disposables that reduce staff burden while improving patient safety and infection control.

Moreover, procurement strategies are shifting in response to supply chain fragility observed during global health crises, prompting stakeholders to diversify supplier bases and explore regional manufacturing partnerships. These combined forces are accelerating an environment where product differentiation rests on clinical outcomes, operational efficiency, and resilience, creating new opportunities for manufacturers and care providers to collaborate on solutions that address both acute clinical needs and longer-term system sustainability.

A rigorous examination of the cumulative implications arising from United States tariff measures in 2025 on devices, supply chains, and procurement strategies within acute respiratory care

The introduction of new tariff measures in the United States during 2025 has exerted multifaceted effects on the clinical technologies and consumables used in acute respiratory distress syndrome management, with cumulative impacts felt throughout procurement, manufacturing, and clinician practice. Elevated import duties on certain medical devices and components have increased landed costs for some advanced systems and disposables, prompting hospital purchasing teams and group purchasing organizations to re-evaluate supplier contracts and to seek alternative sourcing strategies that preserve clinical readiness without compromising quality.

These trade policy changes have accelerated conversations around nearshoring and regional manufacturing for critical components, particularly for complex subsystems used in extracorporeal membrane oxygenation and advanced ventilators. Consequently, device developers and contract manufacturers have had to balance short-term cost pressures with long-term investments in resilient supply architectures. For clinicians, the immediate implication has been a renewed focus on device maintenance, reuse protocols where appropriate and safe, and strategic stock management to mitigate potential disruptions in availability.

In addition, suppliers have increasingly prioritized clarifying total cost of ownership and service-level agreements to reassure institutional purchasers. Regulatory compliance and documentation have come under greater scrutiny as procurement teams demand transparency around component provenance. Taken together, these dynamics have shifted competitive positioning in the sector, favoring manufacturers and distributors capable of demonstrating supply chain transparency, localized support, and adaptive commercial models that can cushion providers against trade-related cost volatility.

Comprehensive segmentation insights that clarify product categories, care pathways, patient cohorts, etiologies, and distribution routes to inform clinical and commercial decision-making

Segmentation insights reveal how distinct product categories, treatment modes, care settings, patient populations, clinical severities, etiologies, and distribution pathways each exert specific influences on clinical decision-making and commercial strategy. Based on product type, the field is studied across ECMO Systems, Prone Positioning Systems, Respiratory Consumables, and Ventilators, with ECMO Systems further distinguished by Veno Arterial and Veno Venous configurations, Prone Positioning Systems categorized into Automated Positioning and Manual Positioning, Respiratory Consumables comprising Airway Circuits, Filters, and Masks and Interfaces, and Ventilators split into Invasive Ventilators and Non Invasive Ventilators, where Invasive Ventilators are further divided into Intensive Care Ventilators and Transport Ventilators while Non Invasive Ventilators include Bi Level Ventilators and Continuous Positive Airway Pressure Ventilators.

Based on treatment mode, the analysis covers ECMO Therapy, Invasive Ventilation, Non Invasive Ventilation, and Prone Positioning, illuminating how clinical pathways and equipment interplay to influence outcomes. Based on end user, care settings such as Ambulatory Care Centers, Home Care Settings, and Hospitals are examined, with Ambulatory Care Centers further explored through Rehabilitation Centers and Specialty Clinics and Hospitals differentiated between Community Hospitals and Teaching Hospitals, clarifying how procurement scale and clinical expertise shape technology adoption.

Based on patient population, adult, neonatal, and pediatric cohorts receive focused attention to reflect varying physiological considerations. Based on severity, clinical categories of mild, moderate, and severe illness inform device selection and escalation protocols. Based on etiology, infectious and noninfectious causes are assessed, with infectious cases further divided into bacterial, fungal, and viral origins and noninfectious causes including aspiration and trauma, each carrying distinct diagnostic and therapeutic implications. Based on distribution channel, procurement pathways encompass Direct Sales, E Commerce, and Third Party Distributors, underlining how route-to-market choices affect availability, service, and total cost considerations.

Key regional insights that compare adoption drivers, regulatory frameworks, and supply chain dynamics across the Americas, Europe Middle East & Africa, and Asia-Pacific

Regional dynamics materially shape the evolution of acute respiratory care technologies, driven by differences in health system organization, regulatory frameworks, and innovation ecosystems. In the Americas, innovation clusters and large tertiary care networks drive early adoption of advanced extracorporeal systems and high-acuity ventilators, while variations in reimbursement models and hospital consolidation patterns influence procurement cycles and service model expectations.

Across Europe, Middle East & Africa, the interplay between diverse regulatory environments and heterogeneous health system financing has fostered both regional centers of clinical excellence and uneven access to advanced therapies. This region shows strong emphasis on interoperability and standardization, as providers seek scalable solutions that can operate across differing clinical capacities and infrastructure constraints. In addition, public-private partnerships and regional manufacturing initiatives play a growing role in addressing supply chain vulnerabilities.

The Asia-Pacific region demonstrates rapid uptake of point-of-care innovations and growing local manufacturing capacity that supports both domestic demand and export opportunities. Demographic trends and rising investment in critical care infrastructure are expanding demand for modular ventilator platforms and consumables tailored to varied clinical settings. Across all regions, the convergence of regulatory harmonization efforts, local manufacturing incentives, and digital health enablement is reshaping how providers evaluate technology value propositions and implement respiratory care solutions.

Key company insights that reveal how product innovation, partnership strategies, and service models are reshaping competitive advantage in acute respiratory care

Company dynamics in the acute respiratory care landscape reflect a balance between established device manufacturers, emerging medtech innovators, and service-oriented distributors that together shape clinical availability and technology evolution. Leading suppliers emphasize integrated solutions that combine hardware reliability, disposables supply chains, and aftersales service, while newer entrants advance niche capabilities such as automated prone positioning, compact extracorporeal modules, and advanced patient interfaces that reduce clinician workload.

Corporate strategies increasingly pair product innovation with managed services, whereby vendors offer bundled maintenance, clinician training, and performance analytics to demonstrate tangible operational improvements. Strategic partnerships and targeted acquisitions are common as firms seek to extend portfolios into complementary technologies and to secure supply chain resilience. Meanwhile, investor interest is directed toward companies that can demonstrate both strong clinical evidence and scalable manufacturing approaches, enabling rapid response during demand surges.

From a competitive perspective, those organizations that prioritize regulatory compliance, clear evidence generation, and reproducible clinical outcomes typically gain preferred-provider status with large hospital systems. In contrast, agile startups focus on rapid iterative development and niche clinical problems, often partnering with academic centers to validate new approaches. Overall, the sector rewards entities that can align clinical relevance with operational viability and transparent service commitments.

Actionable recommendations for industry leaders to align product design, supply resilience, evidence generation, and commercial models with provider priorities and clinical workflows

Industry leaders should pursue integrated strategies that align product development with clinical workflows, supply chain resilience, and demonstrable value for providers. First, device designers and manufacturers must prioritize interoperability and user-centered design, ensuring that new systems integrate seamlessly with existing monitoring platforms and electronic health records to reduce clinician cognitive load and accelerate adoption. By focusing on intuitive interfaces and streamlined maintenance protocols, vendors can lower barriers to sustained clinical use.

Second, strengthening regional supply chains and establishing localized manufacturing or assembly partnerships will mitigate trade-related cost pressures and improve responsiveness to demand fluctuations. Companies should consider hybrid distribution models that combine direct sales for high-touch accounts with vetted third-party distributors and e-commerce channels for consumables, thus balancing service quality with reach.

Third, stakeholders should invest in evidence generation that ties device use to patient-centered outcomes and operational efficiencies, enabling clearer value conversations with payers and hospital administrators. Complementary investments in clinician training, simulation-based competency programs, and post-implementation performance analytics will reinforce clinical confidence and optimize device utilization. Lastly, executives should explore innovative commercial models such as outcome-linked contracts or modular service agreements to align incentives with provider priorities and accelerate diffusion across diverse care settings.

A transparent mixed-methods research methodology blending expert interviews, targeted literature review, and rigorous cross-validation to underpin strategic insights

This analysis employed a mixed-methods research approach that combined qualitative expert interviews, structured device and clinical literature reviews, and cross-sectional analysis of regulatory guidance and procurement practices to produce robust insights. Primary research consisted of conversations with frontline clinicians, biomedical engineers, procurement leaders, and senior executives to capture real-world clinical workflows, device performance considerations, and purchasing priorities. These engagements were designed to surface practical challenges and adoption barriers that may not be fully reflected in peer-reviewed literature.

Secondary research synthesized clinical guidelines, regulatory documents, and published device evaluations to contextualize practice patterns and technological capabilities. Where applicable, industry technical briefs and product manuals were reviewed to understand device specifications and service requirements. The research process incorporated triangulation across multiple information sources to validate findings and to reduce single-source bias.

Throughout the study, a quality assurance protocol was applied, including cross-validation of interview claims, transparent documentation of analytical assumptions, and iterative peer review by domain experts. Ethical considerations included anonymizing participant input and ensuring interviewees represented a balanced cross-section of clinical and commercial perspectives. This methodology supports the credibility of strategic insights while acknowledging inherent limitations tied to evolving clinical evidence and ongoing technological development.

A clear concluding synthesis that underscores collaboration, interoperability, and resilience as the foundations for improving acute respiratory distress syndrome care

In conclusion, acute respiratory distress syndrome care is at an inflection point driven by technological innovation, evolving clinical protocols, and geopolitical forces that influence supply chains and procurement strategies. The convergence of advanced extracorporeal therapies, smarter ventilator platforms, and improved consumables is enabling more nuanced approaches to respiratory support, while digital integration and data-driven decision-making are enhancing the precision and scalability of critical care interventions.

However, translating innovation into sustained clinical benefit requires concerted attention to interoperability, workforce training, evidence generation, and supply chain resilience. Providers and manufacturers that adopt an integrated perspective-one that links device performance to operational workflows and patient outcomes-will be better positioned to deliver value in diverse care settings. As stakeholders adapt to trade policy shifts and regional dynamics, the ability to rapidly demonstrate clinical effectiveness and to assure dependable service will determine long-term competitive positioning.

Ultimately, the pathway forward rests on collaboration among clinicians, manufacturers, distributors, and payers to prioritize solutions that are clinically relevant, operationally feasible, and resilient to external shocks, thereby improving care for patients affected by severe respiratory failure.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Personalized ventilator management protocols leverage real-time lung imaging and AI decision support to optimize ARDS outcomes
  • 5.2. Emerging mesenchymal stem cell therapies demonstrate potential in reducing lung injury and inflammation in ARDS patients
  • 5.3. Growing adoption of extracorporeal membrane oxygenation systems across intensive care units for severe ARDS management
  • 5.4. Integration of digital lung monitoring platforms and predictive analytics to optimize oxygenation strategies in ARDS
  • 5.5. Rising investment and reimbursement support for inhaled nitric oxide delivery systems as adjunctive ARDS therapy
  • 5.6. Development of precision biomarkers for early ARDS diagnosis and personalized therapeutic guidance in critical care

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Acute Respiratory Distress Syndrome Market, by Product Type

  • 8.1. EcmO Systems
    • 8.1.1. Veno Arterial
    • 8.1.2. Veno Venous
  • 8.2. Prone Positioning Systems
    • 8.2.1. Automated Positioning
    • 8.2.2. Manual Positioning
  • 8.3. Respiratory Consumables
    • 8.3.1. Airway Circuits
    • 8.3.2. Filters
    • 8.3.3. Masks And Interfaces
  • 8.4. Ventilators
    • 8.4.1. Invasive Ventilators
      • 8.4.1.1. Intensive Care Ventilators
      • 8.4.1.2. Transport Ventilators
    • 8.4.2. Non Invasive Ventilators
      • 8.4.2.1. Bi Level Ventilators
      • 8.4.2.2. Continuous Positive Airway Pressure Ventilators

9. Acute Respiratory Distress Syndrome Market, by Treatment Mode

  • 9.1. EcmO Therapy
  • 9.2. Invasive Ventilation
  • 9.3. Non Invasive Ventilation
  • 9.4. Prone Positioning

10. Acute Respiratory Distress Syndrome Market, by End User

  • 10.1. Ambulatory Care Centers
    • 10.1.1. Rehabilitation Centers
    • 10.1.2. Specialty Clinics
  • 10.2. Home Care Settings
  • 10.3. Hospitals
    • 10.3.1. Community Hospitals
    • 10.3.2. Teaching Hospitals

11. Acute Respiratory Distress Syndrome Market, by Patient Population

  • 11.1. Adult
  • 11.2. Neonatal
  • 11.3. Pediatric

12. Acute Respiratory Distress Syndrome Market, by Severity

  • 12.1. Mild
  • 12.2. Moderate
  • 12.3. Severe

13. Acute Respiratory Distress Syndrome Market, by Etiology

  • 13.1. Infectious
    • 13.1.1. Bacterial
    • 13.1.2. Fungal
    • 13.1.3. Viral
  • 13.2. Non Infectious
    • 13.2.1. Aspiration
    • 13.2.2. Trauma

14. Acute Respiratory Distress Syndrome Market, by Distribution Channel

  • 14.1. Direct Sales
  • 14.2. E Commerce
  • 14.3. Third Party Distributors

15. Acute Respiratory Distress Syndrome Market, by Region

  • 15.1. Americas
    • 15.1.1. North America
    • 15.1.2. Latin America
  • 15.2. Europe, Middle East & Africa
    • 15.2.1. Europe
    • 15.2.2. Middle East
    • 15.2.3. Africa
  • 15.3. Asia-Pacific

16. Acute Respiratory Distress Syndrome Market, by Group

  • 16.1. ASEAN
  • 16.2. GCC
  • 16.3. European Union
  • 16.4. BRICS
  • 16.5. G7
  • 16.6. NATO

17. Acute Respiratory Distress Syndrome Market, by Country

  • 17.1. United States
  • 17.2. Canada
  • 17.3. Mexico
  • 17.4. Brazil
  • 17.5. United Kingdom
  • 17.6. Germany
  • 17.7. France
  • 17.8. Russia
  • 17.9. Italy
  • 17.10. Spain
  • 17.11. China
  • 17.12. India
  • 17.13. Japan
  • 17.14. Australia
  • 17.15. South Korea

18. Competitive Landscape

  • 18.1. Market Share Analysis, 2024
  • 18.2. FPNV Positioning Matrix, 2024
  • 18.3. Competitive Analysis
    • 18.3.1. Koninklijke Philips N.V.
    • 18.3.2. Medtronic plc
    • 18.3.3. General Electric Company
    • 18.3.4. Dragerwerk AG & Co. KGaA
    • 18.3.5. Hamilton Medical AG
    • 18.3.6. ResMed Inc.
    • 18.3.7. Getinge AB
    • 18.3.8. Fisher & Paykel Healthcare Corporation Limited
    • 18.3.9. Mindray Medical International Limited
    • 18.3.10. Nihon Kohden Corporation

LIST OF FIGURES

  • FIGURE 1. GLOBAL ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY TREATMENT MODE, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY TREATMENT MODE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY END USER, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY END USER, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY PATIENT POPULATION, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY PATIENT POPULATION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY SEVERITY, 2024 VS 2032 (%)
  • FIGURE 11. GLOBAL ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY SEVERITY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY ETIOLOGY, 2024 VS 2032 (%)
  • FIGURE 13. GLOBAL ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY ETIOLOGY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. GLOBAL ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2032 (%)
  • FIGURE 15. GLOBAL ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. GLOBAL ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. AMERICAS ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. NORTH AMERICA ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. LATIN AMERICA ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. EUROPE, MIDDLE EAST & AFRICA ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. EUROPE ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. MIDDLE EAST ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. AFRICA ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. ASIA-PACIFIC ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. GLOBAL ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. ASEAN ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. GCC ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 28. EUROPEAN UNION ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 29. BRICS ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 30. G7 ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 31. NATO ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 32. GLOBAL ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 33. ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 34. ACUTE RESPIRATORY DISTRESS SYNDROME MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY ECMO SYSTEMS, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY ECMO SYSTEMS, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY ECMO SYSTEMS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY ECMO SYSTEMS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY ECMO SYSTEMS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY ECMO SYSTEMS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY ECMO SYSTEMS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY ECMO SYSTEMS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY VENO ARTERIAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY VENO ARTERIAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY VENO ARTERIAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY VENO ARTERIAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY VENO ARTERIAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY VENO ARTERIAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY VENO VENOUS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY VENO VENOUS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY VENO VENOUS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY VENO VENOUS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY VENO VENOUS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY VENO VENOUS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY PRONE POSITIONING SYSTEMS, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY PRONE POSITIONING SYSTEMS, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY PRONE POSITIONING SYSTEMS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY PRONE POSITIONING SYSTEMS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY PRONE POSITIONING SYSTEMS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY PRONE POSITIONING SYSTEMS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY PRONE POSITIONING SYSTEMS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY PRONE POSITIONING SYSTEMS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY AUTOMATED POSITIONING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY AUTOMATED POSITIONING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY AUTOMATED POSITIONING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY AUTOMATED POSITIONING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY AUTOMATED POSITIONING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY AUTOMATED POSITIONING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY MANUAL POSITIONING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY MANUAL POSITIONING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY MANUAL POSITIONING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY MANUAL POSITIONING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY MANUAL POSITIONING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY MANUAL POSITIONING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY RESPIRATORY CONSUMABLES, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY RESPIRATORY CONSUMABLES, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY RESPIRATORY CONSUMABLES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY RESPIRATORY CONSUMABLES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY RESPIRATORY CONSUMABLES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY RESPIRATORY CONSUMABLES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY RESPIRATORY CONSUMABLES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY RESPIRATORY CONSUMABLES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY AIRWAY CIRCUITS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY AIRWAY CIRCUITS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY AIRWAY CIRCUITS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY AIRWAY CIRCUITS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY AIRWAY CIRCUITS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY AIRWAY CIRCUITS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY FILTERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY FILTERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY FILTERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY FILTERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY FILTERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY FILTERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY MASKS AND INTERFACES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY MASKS AND INTERFACES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY MASKS AND INTERFACES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY MASKS AND INTERFACES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY MASKS AND INTERFACES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY MASKS AND INTERFACES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY VENTILATORS, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY VENTILATORS, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY VENTILATORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY VENTILATORS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY VENTILATORS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY VENTILATORS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY VENTILATORS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY VENTILATORS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY INVASIVE VENTILATORS, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY INVASIVE VENTILATORS, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY INVASIVE VENTILATORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY INVASIVE VENTILATORS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY INVASIVE VENTILATORS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY INVASIVE VENTILATORS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY INVASIVE VENTILATORS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY INVASIVE VENTILATORS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY INTENSIVE CARE VENTILATORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY INTENSIVE CARE VENTILATORS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY INTENSIVE CARE VENTILATORS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY INTENSIVE CARE VENTILATORS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY INTENSIVE CARE VENTILATORS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY INTENSIVE CARE VENTILATORS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY TRANSPORT VENTILATORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY TRANSPORT VENTILATORS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY TRANSPORT VENTILATORS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY TRANSPORT VENTILATORS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY TRANSPORT VENTILATORS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY TRANSPORT VENTILATORS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY NON INVASIVE VENTILATORS, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY NON INVASIVE VENTILATORS, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY NON INVASIVE VENTILATORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY NON INVASIVE VENTILATORS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY NON INVASIVE VENTILATORS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY NON INVASIVE VENTILATORS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY NON INVASIVE VENTILATORS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY NON INVASIVE VENTILATORS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY BI LEVEL VENTILATORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY BI LEVEL VENTILATORS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY BI LEVEL VENTILATORS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY BI LEVEL VENTILATORS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY BI LEVEL VENTILATORS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY BI LEVEL VENTILATORS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY CONTINUOUS POSITIVE AIRWAY PRESSURE VENTILATORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY CONTINUOUS POSITIVE AIRWAY PRESSURE VENTILATORS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY CONTINUOUS POSITIVE AIRWAY PRESSURE VENTILATORS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY CONTINUOUS POSITIVE AIRWAY PRESSURE VENTILATORS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY CONTINUOUS POSITIVE AIRWAY PRESSURE VENTILATORS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY CONTINUOUS POSITIVE AIRWAY PRESSURE VENTILATORS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY TREATMENT MODE, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY TREATMENT MODE, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY ECMO THERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY ECMO THERAPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY ECMO THERAPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY ECMO THERAPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY ECMO THERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY ECMO THERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY INVASIVE VENTILATION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY INVASIVE VENTILATION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 131. GLOBAL ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY INVASIVE VENTILATION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY INVASIVE VENTILATION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 133. GLOBAL ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY INVASIVE VENTILATION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY INVASIVE VENTILATION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 135. GLOBAL ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY NON INVASIVE VENTILATION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 136. GLOBAL ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY NON INVASIVE VENTILATION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 137. GLOBAL ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY NON INVASIVE VENTILATION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 138. GLOBAL ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY NON INVASIVE VENTILATION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 139. GLOBAL ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY NON INVASIVE VENTILATION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 140. GLOBAL ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY NON INVASIVE VENTILATION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 141. GLOBAL ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY PRONE POSITIONING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 142. GLOBAL ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY PRONE POSITIONING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 143. GLOBAL ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY PRONE POSITIONING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 144. GLOBAL ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY PRONE POSITIONING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 145. GLOBAL ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY PRONE POSITIONING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 146. GLOBAL ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY PRONE POSITIONING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 147. GLOBAL ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 148. GLOBAL ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 149. GLOBAL ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY AMBULATORY CARE CENTERS, 2018-2024 (USD MILLION)
  • TABLE 150. GLOBAL ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY AMBULATORY CARE CENTERS, 2025-2032 (USD MILLION)
  • TABLE 151. GLOBAL ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY AMBULATORY CARE CENTERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 152. GLOBAL ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY AMBULATORY CARE CENTERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 153. GLOBAL ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY AMBULATORY CARE CENTERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 154. GLOBAL ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY AMBULATORY CARE CENTERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 155. GLOBAL ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY AMBULATORY CARE CENTERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 156. GLOBAL ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY AMBULATORY CARE CENTERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 157. GLOBAL ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY REHABILITATION CENTERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 158. GLOBAL ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY REHABILITATION CENTERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 159. GLOBAL ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY REHABILITATION CENTERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 160. GLOBAL ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY REHABILITATION CENTERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 161. GLOBAL ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY REHABILITATION CENTERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 162. GLOBAL ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY REHABILITATION CENTERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 163. GLOBAL ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 164. GLOBAL ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 165. GLOBAL ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY SPECIALTY CLINICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 166. GLOBAL ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY SPECIALTY CLINICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 167. GLOBAL ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY SPECIALTY CLINICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 168. GLOBAL ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY SPECIALTY CLINICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 169. GLOBAL ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY HOME CARE SETTINGS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 170. GLOBAL ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY HOME CARE SETTINGS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 171. GLOBAL ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY HOME CARE SETTINGS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 172. GLOBAL ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY HOME CARE SETTINGS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 173. GLOBAL ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY HOME CARE SETTINGS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 174. GLOBAL ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY HOME CARE SETTINGS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 175. GLOBAL ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
  • TABLE 176. GLOBAL ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY HOSPITALS, 2025-2032 (USD MILLION)
  • TABLE 177. GLOBAL ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 178. GLOBAL ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY HOSPITALS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 179. GLOBAL ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 180. GLOBAL ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY HOSPITALS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 181. GLOBAL ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 182. GLOBAL ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 183. GLOBAL ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY COMMUNITY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 184. GLOBAL ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY COMMUNITY HOSPITALS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 185. GLOBAL ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY COMMUNITY HOSPITALS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 186. GLOBAL ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY COMMUNITY HOSPITALS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 187. GLOBAL ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY COMMUNITY HOSPITALS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 188. GLOBAL ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY COMMUNITY HOSPITALS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 189. GLOBAL ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY TEACHING HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 190. GLOBAL ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY TEACHING HOSPITALS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 191. GLOBAL ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY TEACHING HOSPITALS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 192. GLOBAL ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY TEACHING HOSPITALS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 193. GLOBAL ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY TEACHING HOSPITALS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 194. GLOBAL ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY TEACHING HOSPITALS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 195. GLOBAL ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY PATIENT POPULATION, 2018-2024 (USD MILLION)
  • TABLE 196. GLOBAL ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY PATIENT POPULATION, 2025-2032 (USD MILLION)
  • TABLE 197. GLOBAL ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY ADULT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 198. GLOBAL ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY ADULT, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 199. GLOBAL ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY ADULT, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 200. GLOBAL ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY ADULT, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 201. GLOBAL ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY ADULT, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 202. GLOBAL ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY ADULT, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 203. GLOBAL ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY NEONATAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 204. GLOBAL ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY NEONATAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 205. GLOBAL ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY NEONATAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 206. GLOBAL ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY NEONATAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 207. GLOBAL ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY NEONATAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 208. GLOBAL ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY NEONATAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 209. GLOBAL ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY PEDIATRIC, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 210. GLOBAL ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY PEDIATRIC, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 211. GLOBAL ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY PEDIATRIC, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 212. GLOBAL ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY PEDIATRIC, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 213. GLOBAL ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY PEDIATRIC, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 214. GLOBAL ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY PEDIATRIC, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 215. GLOBAL ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY SEVERITY, 2018-2024 (USD MILLION)
  • TABLE 216. GLOBAL ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY SEVERITY, 2025-2032 (USD MILLION)
  • TABLE 217. GLOBAL ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY MILD, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 218. GLOBAL ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY MILD, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 219. GLOBAL ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY MILD, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 220. GLOBAL ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY MILD, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 221. GLOBAL ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY MILD, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 222. GLOBAL ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY MILD, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 223. GLOBAL ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY MODERATE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 224. GLOBAL ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY MODERATE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 225. GLOBAL ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY MODERATE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 226. GLOBAL ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY MODERATE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 227. GLOBAL ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY MODERATE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 228. GLOBAL ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY MODERATE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 229. GLOBAL ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY SEVERE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 230. GLOBAL ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY SEVERE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 231. GLOBAL ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY SEVERE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 232. GLOBAL ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY SEVERE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 233. GLOBAL ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY SEVERE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 234. GLOBAL ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY SEVERE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 235. GLOBAL ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY ETIOLOGY, 2018-2024 (USD MILLION)
  • TABLE 236. GLOBAL ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY ETIOLOGY, 2025-2032 (USD MILLION)
  • TABLE 237. GLOBAL ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY INFECTIOUS, 2018-2024 (USD MILLION)
  • TABLE 238. GLOBAL ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY INFECTIOUS, 2025-2032 (USD MILLION)
  • TABLE 239. GLOBAL ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY INFECTIOUS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 240. GLOBAL ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY INFECTIOUS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 241. GLOBAL ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY INFECTIOUS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 242. GLOBAL ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY INFECTIOUS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 243. GLOBAL ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY INFECTIOUS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 244. GLOBAL ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY INFECTIOUS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 245. GLOBAL ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY BACTERIAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 246. GLOBAL ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY BACTERIAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 247. GLOBAL ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY BACTERIAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 248. GLOBAL ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY BACTERIAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 249. GLOBAL ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY BACTERIAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 250. GLOBAL ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY BACTERIAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 251. GLOBAL ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY FUNGAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 252. GLOBAL ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY FUNGAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 253. GLOBAL ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY FUNGAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 254. GLOBAL ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY FUNGAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 255. GLOBAL ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY FUNGAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 256. GLOBAL ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY FUNGAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 257. GLOBAL ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY VIRAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 258. GLOBAL ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY VIRAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 259. GLOBAL ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY VIRAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 260. GLOBAL ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY VIRAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 261. GLOBAL ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY VIRAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 262. GLOBAL ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY VIRAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 263. GLOBAL ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY NON INFECTIOUS, 2018-2024 (USD MILLION)
  • TABLE 264. GLOBAL ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY NON INFECTIOUS, 2025-2032 (USD MILLION)
  • TABLE 265. GLOBAL ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY NON INFECTIOUS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 266. GLOBAL ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY NON INFECTIOUS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 267. GLOBAL ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY NON INFECTIOUS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 268. GLOBAL ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY NON INFECTIOUS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 269. GLOBAL ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY NON INFECTIOUS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 270. GLOBAL ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY NON INFECTIOUS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 271. GLOBAL ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY ASPIRATION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 272. GLOBAL ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY ASPIRATION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 273. GLOBAL ACUTE RESPIRAT